Cancer clot-prevention review finds uncertain benefit and a bleeding signal
Trials comparing Factor Xa inhibitors with placebo left clot prevention uncertain and raised concern about major bleeding.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The pooled estimate suggested fewer venous blood clots with Factor Xa inhibitors, but the result was not statistically significant and uncertainty was wide. Major bleeding showed a signal toward increased risk. The balance between possible clot prevention and bleeding remains unresolved for the cancer populations represented in these trials.
This abstract-based explanation cannot establish the practical benefit–harm balance: events were few, confidence intervals were wide, and the abstract provides neither absolute event rates nor follow-up durations.
What researchers found
Venous blood clot incidence
Factor Xa inhibitors versus placebo; follow-up timing unavailable. This relative-risk estimate was not statistically significant; its uncertainty interval spans both lower and higher clot risk.
An uncertain prevention estimate
The central estimate favors fewer clots, but the range of uncertainty also allows increased risk. The pooled result therefore does not establish a preventive benefit, despite the direction of the estimate.
Bleeding outcomes differed
Major bleeding raised concern. Clinically relevant bleeding classified as non-major showed no statistically significant difference between groups. That finding does not establish equal safety, and the authors describe the evidence overall as inconclusive.
The original publication
Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis.
Kamil A, Kumar SP, Zulfiqar R et al.
Clin Appl Thromb Hemost · 2025
- PubMed ID
- 40910473
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.